kabutan

Kyowa Kirin Co., Ltd.(4151) Summary

4151
TSE Prime
Kyowa Kirin Co., Ltd.
2,492.0
JPY
+2.5
(+0.10%)
Jan 29, 3:30 pm JST
16.29
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
22.8
PBR
1.54
Yield
2.41%
Margin Trading Ratio
33.62
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
2,457.5 JPY 16.05 USD
Previous Close Jan 28
2,489.5 JPY 16.31 USD
High Jan 29, 3:05 pm
2,503.0 JPY 16.35 USD
Low Jan 29, 9:00 am
2,451.0 JPY 16.01 USD
Volume
1,112,000
Trading Value
2.77B JPY 0.02B USD
VWAP
2489.42 JPY 16.27 USD
Minimum Trading Value
249,200 JPY 1,629 USD
Market Cap
1.31T JPY 8.62B USD
Number of Trades
2,982
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
2,885
1-Year High May 2, 2025
11,280
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 45,700 83,300 1.82
Jan 16, 2026 43,200 131,700 3.05
Jan 9, 2026 41,100 159,100 3.87
Dec 26, 2025 79,400 166,000 2.09
Dec 19, 2025 50,500 165,100 3.27
Company Profile
Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Group, focusing on pharmaceutical business and new drug development through its biotechnology division. The company has formed a partnership with Fujifilm.
Sector
Pharmaceuticals
Kyowa Kirin Co., Ltd. primarily engages in the manufacture and sale of prescription pharmaceuticals. The company has numerous subsidiaries and equity-method affiliates, with Kirin Holdings as its parent company. Kyowa Kirin operates globally, with a particular focus on four key markets: Japan, North America, Europe, and Asia-Oceania. The company excels in biopharmaceutical development, possessing a unique drug discovery platform centered on antibody drug development and manufacturing technologies. Kyowa Kirin concentrates on creating new drugs that address unmet medical needs, particularly in disease areas such as nephrology, oncology, and immunology-allergy.